DNA plasmid coding for Phlebotomus sergenti salivary protein PsSP9, a member of the SP15 family of proteins, protects against Leishmania tropica.
Animals
Disease Models, Animal
Female
Hypersensitivity, Delayed
Interferon-gamma
/ biosynthesis
Leishmania tropica
/ immunology
Leishmaniasis, Cutaneous
/ prevention & control
Mice, Inbred BALB C
Phlebotomus
/ genetics
Salivary Proteins and Peptides
/ genetics
Vaccines, DNA
/ administration & dosage
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
31
07
2018
accepted:
10
12
2018
revised:
24
01
2019
pubmed:
12
1
2019
medline:
12
2
2019
entrez:
12
1
2019
Statut:
epublish
Résumé
The vector-borne disease leishmaniasis is transmitted to humans by infected female sand flies, which transmits Leishmania parasites together with saliva during blood feeding. In Iran, cutaneous leishmaniasis (CL) is caused by Leishmania (L.) major and L. tropica, and their main vectors are Phlebotomus (Ph.) papatasi and Ph. sergenti, respectively. Previous studies have demonstrated that mice immunized with the salivary gland homogenate (SGH) of Ph. papatasi or subjected to bites from uninfected sand flies are protected against L. major infection. In this work we tested the immune response in BALB/c mice to 14 different plasmids coding for the most abundant salivary proteins of Ph. sergenti. The plasmid coding for the salivary protein PsSP9 induced a DTH response in the presence of a significant increase of IFN-γ expression in draining lymph nodes (dLN) as compared to control plasmid and no detectable PsSP9 antibody response. Animals immunized with whole Ph. sergenti SGH developed only a saliva-specific antibody response and no DTH response. Mice immunized with whole Ph. sergenti saliva and challenged intradermally with L. tropica plus Ph. sergenti SGH in their ears, exhibited no protective effect. In contrast, PsSP9-immunized mice showed protection against L. tropica infection resulting in a reduction in nodule size, disease burden and parasite burden compared to controls. Two months post infection, protection was associated with a significant increase in the ratio of IFN-γ to IL-5 expression in the dLN compared to controls. This study demonstrates that while immunity to the whole Ph. sergenti saliva does not induce a protective response against cutaneous leishmaniasis in BALB/c mice, PsSP9, a member of the PpSP15 family of Ph. sergenti salivary proteins, provides protection against L. tropica infection. These results suggest that this family of proteins in Ph. sergenti, Ph. duboscqi and Ph. papatasi may have similar immunogenic and protective properties against different Leishmania species. Indeed, this anti-saliva immunity may act as an adjuvant to accelerate the cell-mediated immune response to co-administered Leishmania antigens, or even cause the activation of infected macrophages to remove parasites more efficiently. These findings highlight the idea of applying arthropod saliva components in vaccination approaches for diseases caused by vector-borne pathogens.
Sections du résumé
BACKGROUND
The vector-borne disease leishmaniasis is transmitted to humans by infected female sand flies, which transmits Leishmania parasites together with saliva during blood feeding. In Iran, cutaneous leishmaniasis (CL) is caused by Leishmania (L.) major and L. tropica, and their main vectors are Phlebotomus (Ph.) papatasi and Ph. sergenti, respectively. Previous studies have demonstrated that mice immunized with the salivary gland homogenate (SGH) of Ph. papatasi or subjected to bites from uninfected sand flies are protected against L. major infection.
METHODS AND RESULTS
In this work we tested the immune response in BALB/c mice to 14 different plasmids coding for the most abundant salivary proteins of Ph. sergenti. The plasmid coding for the salivary protein PsSP9 induced a DTH response in the presence of a significant increase of IFN-γ expression in draining lymph nodes (dLN) as compared to control plasmid and no detectable PsSP9 antibody response. Animals immunized with whole Ph. sergenti SGH developed only a saliva-specific antibody response and no DTH response. Mice immunized with whole Ph. sergenti saliva and challenged intradermally with L. tropica plus Ph. sergenti SGH in their ears, exhibited no protective effect. In contrast, PsSP9-immunized mice showed protection against L. tropica infection resulting in a reduction in nodule size, disease burden and parasite burden compared to controls. Two months post infection, protection was associated with a significant increase in the ratio of IFN-γ to IL-5 expression in the dLN compared to controls.
CONCLUSION
This study demonstrates that while immunity to the whole Ph. sergenti saliva does not induce a protective response against cutaneous leishmaniasis in BALB/c mice, PsSP9, a member of the PpSP15 family of Ph. sergenti salivary proteins, provides protection against L. tropica infection. These results suggest that this family of proteins in Ph. sergenti, Ph. duboscqi and Ph. papatasi may have similar immunogenic and protective properties against different Leishmania species. Indeed, this anti-saliva immunity may act as an adjuvant to accelerate the cell-mediated immune response to co-administered Leishmania antigens, or even cause the activation of infected macrophages to remove parasites more efficiently. These findings highlight the idea of applying arthropod saliva components in vaccination approaches for diseases caused by vector-borne pathogens.
Identifiants
pubmed: 30633742
doi: 10.1371/journal.pntd.0007067
pii: PNTD-D-18-01170
pmc: PMC6345478
doi:
Substances chimiques
Salivary Proteins and Peptides
0
Vaccines, DNA
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007067Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS Negl Trop Dis. 2014 Mar 27;8(3):e2751
pubmed: 24675711
Infect Immun. 1996 Dec;64(12):5442-5
pubmed: 8945606
Parasitol Int. 2009 Mar;58(1):1-5
pubmed: 18768167
Science. 2000 Nov 17;290(5495):1351-4
pubmed: 11082061
PLoS Negl Trop Dis. 2008 Apr 16;2(4):e226
pubmed: 18414648
J Exp Med. 2001 Aug 6;194(3):331-42
pubmed: 11489952
PLoS Pathog. 2009 May;5(5):e1000441
pubmed: 19461875
PLoS Negl Trop Dis. 2011 Mar 29;5(3):e943
pubmed: 21468307
Immunotherapy. 2017 Oct;9(13):1089-1102
pubmed: 29032739
Prog Clin Biol Res. 1980;47:259-85
pubmed: 7010374
Nat Rev Immunol. 2003 Nov;3(11):867-78
pubmed: 14668803
Bull Soc Pathol Exot Filiales. 1983 Aug-Oct;76(4):377-83
pubmed: 6354498
Mol Immunol. 2015 Oct;67(2 Pt B):501-11
pubmed: 26298575
Infect Immun. 2004 Mar;72(3):1240-7
pubmed: 14977924
J Invest Dermatol. 2012 Dec;132(12):2735-43
pubmed: 22739793
PLoS Negl Trop Dis. 2017 Jul 14;11(7):e0005774
pubmed: 28708893
J Pharm Pharm Sci. 2010;13(3):320-35
pubmed: 21092706
PLoS Negl Trop Dis. 2016 Nov 3;10(11):e0005078
pubmed: 27812113
J Immunol. 2001 Nov 1;167(9):5226-30
pubmed: 11673536
Front Cell Infect Microbiol. 2012 Jun 12;2:83
pubmed: 22919674
J Exp Med. 1998 Nov 16;188(10):1941-53
pubmed: 9815271
BMC Microbiol. 2013 May 08;13:102
pubmed: 23656976
Immunology. 2009 Sep;128(1 Suppl):e652-60
pubmed: 19740326
Int J Parasitol. 2011 Apr;41(5):481-5
pubmed: 21310158
Microbes Infect. 2005 Apr;7(4):760-6
pubmed: 15866511
Microbes Infect. 2000 Nov;2(14):1765-73
pubmed: 11137049
Front Immunol. 2012 May 11;3:110
pubmed: 22593758
PLoS One. 2012;7(5):e35671
pubmed: 22693548
J Clin Microbiol. 2011 Nov;49(11):3892-904
pubmed: 22042830
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7845-50
pubmed: 18509051
Comp Med. 2001 Oct;51(5):443-56
pubmed: 11924805
J Immunol. 2005 Jun 1;174(11):7160-71
pubmed: 15905560
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Sci Transl Med. 2015 Jun 3;7(290):290ra90
pubmed: 26041707
Science. 1988 Mar 11;239(4845):1306-8
pubmed: 3344436
PLoS Negl Trop Dis. 2014 Apr 24;8(4):e2781
pubmed: 24762408
PLoS Negl Trop Dis. 2007 Nov 28;1(2):e84
pubmed: 18060088
J Biol Chem. 2011 Sep 16;286(37):32383-93
pubmed: 21795673
PLoS Negl Trop Dis. 2013 May 23;7(5):e2242
pubmed: 23717705
Wkly Epidemiol Rec. ;92(38):557-65
pubmed: 28945057
Eur J Immunol. 2007 Nov;37(11):3111-21
pubmed: 17935072
J Immunol. 2001 Dec 15;167(12):6967-74
pubmed: 11739516